Takeda America takes over URL Pharma
Takeda will begin the integration of URL Pharma and will right away assume responsibility for the marketing and promotion of URL’s Colcrys (colchicine) for the treatment and prevention
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).
The manufacturing plant produces D-Ribose, through quality fermentation and applied extraction and refinement techniques, the company said. Bioenergy Life Science president Tom VonderBrink said that the BRC accreditation